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Abstract
Background: Benzodiazepines (BDZ) are the largest-selling drug group in the world. The
potential of dependence with BDZ has been known for almost three decades now. In countries like
Pakistan where laws against unlicensed sale of BDZ are not implemented vigorously the risk of
misuse of and dependence on these drugs is even higher. Previous studies have shown that BDZ
prevalence among patients/visitors to general outpatient clinics in Pakistan may be as high as 30%.
However, no research has been carried out on the prevalence of BDZ use in psychiatric patients
in Pakistan.
Methods: We carried out a cross-sectional survey over 3 months in psychiatry outpatient clinics
of two tertiary care hospitals in Karachi and Lahore. Besides basic socio-demographic data the
participants were asked if they were taking a BDZ at present and if yes, the frequency, route and
dosage of the drug, who had initiated the drug and why it had been prescribed. We used chi-square
test and t-test to find out which socio-demographic or clinical factors were associated with an
increased risk of BDZ use. We used Logistic Regression to find out which variable(s) best predicted
the increased likelihood of BDZ use.
Results: Out of a total of 419 participants 187 (45%) of the participants had been currently using
at least one BDZ. Seventy-three percent of the users had been using the drug for 4 weeks or longer
and 87% were taking it every day. In 90% of cases the BDZ had been initiated by a doctor, who was
a psychiatrist in 70% of the cases. Female gender, increasing age, living in Lahore, and having seen
a psychiatrist before, were associated with an increased likelihood of using BDZ.
Conclusion: The study shows how high BDZ use is in psychiatric outpatients in Pakistan. Most of
the users were taking it for a duration and with a frequency which puts them at risk of becoming
dependent on BDZ. In most of the cases it had been initiated by a doctor. Both patients and doctors
need to be made aware of the risk of dependence associated with the use of BDZ.
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After the discovery of Chlordiazepoxide in 1957 benzodi-
azepines (BDZ) soon became and still are the best-selling
drugs in the world [1,2]. However, as early as in 1970s
reports suggesting an association between long-term use of
these drugs and tolerance started appearing in the medical
literature. In 1981 Petrusson and Lader showed conclu-
sively that a physiological withdrawal syndrome could
develop with use of BDZ in doses considered to be in the
therapeutic range [3]. The risk of dependence was esti-
mated to be as high as 45% after 6 months of continuous
use [3,4]. Since then concerns about dependence and with-
drawal have prompted drug regulatory agencies of many
countries to place restrictions on prescribing and over-the-
counter sales of BDZ [5]. In many countries BDZ are
licensed only for the short-term treatment of anxiety and
insomnia, as a pre-anaesthetic and for alcohol detoxifica-
tion [6]. In Pakistan while legally the BDZ can be purchased
only after producing a doctor's prescription, at a practical
level they can be very easily purchased without one.
Depending on the definition of BDZ use, period of obser-
vation and the population studied, estimates of BDZ use
prevalence have ranged from as low as 0.2% to as high as
86% [7,8]. Generally, studies done on the general popula-
tion report lower prevalence rates than those done in med-
ically and psychiatrically ill population, and inpatient
populations higher than outpatient populations [2,7-15].
A few studies have been conducted on the use of BDZ in
Pakistan. The study by Raoof et al[16] showed that among
patients and visitors at the outpatient clinics of a tertiary
care hospital in Karachi 30.4% had used BDZ at some
point in their life and 42% of the users had been using it
for more than a year. Another study from Karachi showed
21.2% of inpatients at a tertiary care hospital were being
prescribed BDZ[11] We did not come across any study
exploring the pattern of BDZ use in psychiatric inpatient
and outpatient populations in Pakistan.
In this study we wanted to find out the prevalence and
pattern of BDZ use in psychiatric out patients in Pakistan.
We also want to find out if there are any demographic or
clinical variables that are associated with an increased
likelihood of using BDZ in these populations, whose deci-
sion was it to start these medications, and why were they
started in the first place.
Methods
The study was conducted simultaneously in two tertiary
care hospitals in Pakistan, the Aga Khan University Hospi-
tal in Karachi, and Fatima Memorial Hospital in Lahore.
Both hospitals are private, fee-paying though the services
at the latter are heavily subsidized and fees are much
lower. Ethical approval for conducting the study was
obtained from Ethical Review Committees of both the
hospitals.
Subjects
All patients attending the psychiatry outpatient clinics at
both the centres for the first time (Initial patients) were
eligible to be recruited in the study. There was no restric-
tion on age as in Pakistan BDZ are sometimes used as
antiepileptics, as well as on psychiatric diagnosis or any
other variables. Only Initial patients were included as we
did not wish the data to be influenced by the practice of
consultant psychiatrists at the two centres.
Data collection
Data was collected from May to July 2008. All consecutive
patients attending the clinics during this period were
invited to participate in the study. The data was collected
from Monday to Friday, 9 am to 5 pm in Karachi, and
Monday to Saturday 9 am to 2 pm in Lahore. As data was
collected by one junior doctor each on both the sites
because of the heavy volumes it was not possible to con-
tact all the initial patients who attended the two clinics
during this period. The number and details of those initial
patients who could not be contacted, and details of those
who refused to participate were not recorded.
The data was collected using a specially designed data col-
lection form. The participants were initially asked for socio-
demographic information like age, gender, marital status,
education and occupation. They were then asked if they
had ever seen a psychiatrist before their index consultation.
The psychiatric diagnoses were recorded from the medical
notes after the patients had been seen by the consultant
psychiatrists at the participating institutions on their index
(1st) visit.
The patients were then asked for the list of the medications
they had been taking immediately prior to their index con-
sultation and it was checked if they were taking any BDZ.
Those who were found to be taking a BDZ were asked the
duration, frequency, dose and route of drug use. They were
asked who had first initiated the BDZ (as it is not uncom-
mon in Pakistan for people to start taking a sleeping or anx-
iety pill themselves, or at the advice of a friend or a
pharmacy salesman without any need for a prescription),
and why the BDZ had been started initially. Diazepam
equivalent doses were calculated using the Maudsley Pre-
scribing Guidelines (page 199) [17]. The diazepam equiva-
lent dose of bromazepam was not given in these guidelines
or in Lexi-Comp's Drug Information Handbook so was
taken from the benzo.org.uk website [18]
Sample size requirements
Assuming the anticipated prevalence of benzodiazepine
use at a tertiary care hospital as 30% and taking the preci-Page 2 of 6
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5% level of significance and 80% power.
Data analysis
Analyses were done in SPSS 16.0. We used chi-squared
test to analyse categorical variables like gender, city,
whether they had ever seen a psychiatrist before the index
presentation, etc, and t-test to analyse continuous varia-
bles like age. We performed Logistic Regression to find out
which variable(s) best predicted the likelihood of some-
one taking a BDZ. We used BDZ taking as the dependent
variable and the variables which were statistically signifi-
cant or very close to statistical significance (age, gender,
occupation, city, ever seen a psychiatrist before, and psy-
chiatric diagnosis) as independent variables, entering all
the variables at the same time. P value less than 0.05 was
considered statistically significant.
Results and discussion
Analysis of pooled data
A total of 419 patients participated in the study, 225 in
Karachi and 194 in Lahore. Median age of the participants
was 30 years with an inter-quartile range of 24–42 years
(range 5–86 years). Fifty-eight percent of the participants
were male, 60% were married while 37% were single.
Housewives (28%) were the largest occupational group,
followed by unemployed (25%), skilled labourers (16%)
and students (11%). Fifty eight percent of the participants
had received at least secondary or higher education.
Sixty eight percent of participants had already seen a psy-
chiatrist prior to being interviewed for this study. In terms
of ICD-10 diagnosis about half (49.5%) of the partici-
pants were suffering from Mood (affective) disorders, fol-
lowed by Schizophrenia, schizotypal and delusional
disorders (23.6%), and Neurotic, stress-related and
somatoform disorders (11.3%). About 7% of participants
were not suffering from any psychiatric illness.
About 24% of the subjects, from Karachi reported to be
suffering from cardiovascular diseases, including hyper-
tension and ischemic heart disease. The proportion was
found to be 6% among the subjects from Lahore. Diabetes
mellitus was present among 10% of Karachi subjects and
about 2% from Lahore. About 5% and 2% of subjects also
reported to have gastro-intestinal problems from Karachi
and Lahore, respectively (Data not shown).
Forty five percent (187/419) of participants reported that
they were currently taking at least one BDZ. Of these, 176
patients were taking one, 11 were taking two and one was
taking three BDZ. Frequency of the particular BDZ being
taken was clonazepam 31.4%, lorazepam 23.9%, alpra-
zolam 20.2%, bromazepam 14.9%, diazepam 9.6%, fol-
lowed by midazolam, clobazam, and temazepam each
taken by 0.5 to one percent of patients. The median
diazepam equivalent dosage being taken was 7.49 milli-
grams with an inter-quartile range of 5–20 milligrams.
Participants had been taking the drug for a median dura-
tion of 12 weeks, with an inter-quartile range of 3–48
weeks. However, the range was very wide extending from
1 to 1440 weeks. Among users 73% (137/187) had been
taking the drug for four or more weeks and 22% (41/187)
(9.8% of the total sample) for more than one year. About
87% of the respondents were taking the BDZ daily, 3.7%
about once a week, 5.9% less than once a week and 3.2%
less than once a month. Almost all (98.4%) the patients
were taking the drug orally with only one patient each tak-
ing it intramuscularly and intravenously.
In 70% of the cases the drug had been started by a psychi-
atrist while in 10% of cases the participants had started
using the drug themselves. The drug had been initiated by
a family physician in 8.6% of the cases, internist 6.4%,
and other physicians and relatives in 0.5–2% of the cases.
In 73% of the cases the drug was being prescribed/taken
for insomnia, 12% relaxation, 10% anxiety and in 3.2% as
antiepileptic.
The group taking BDZ was slightly older than the group
which was not (mean age 35.8 vs 32.5 years, p = 0.02).
The association between basic sociodemographic and
clinical data, and the likelihood of taking benzodi-
azepines, is shown in Table 1. Occupation, city of resi-
dence, and the fact that a participant had previously seen
a psychiatrist, were all statistically significantly associated
with taking BDZ, while female gender and ICD-10 diag-
nosis were marginally statistically significant.
The results of Simple Multiple Logistic Regression analysis
are shown in Table 2. Age, gender and city of residence
were the strongest predictors of the likelihood of someone
taking a BDZ, while having previously seen a psychiatrist
was at the margin of statistical significance.
Differences between cities
We also analysed the data to see if there were differences
between participants living in Karachi or Lahore in terms
of their BDZ use. There was a statistically significant differ-
ence between Karachi and Lahore in the prevalence of psy-
chiatric outpatients taking benzodiazepines, with more
people in Lahore than in Karachi taking benzodiazepines
(52.6% vs 38.2%, p = 0.004). There were gender-wise dif-
ferences between cities in terms of BDZ use. In Karachi
females were significantly more likely to take BDZ (F:M =
48% vs 31%, p = 0.01). However, no such difference was
seen in Lahore (F:M = 54.5% vs 51.7%, p = 0.77). There
was a huge difference between cities in terms of who had
initiated the BDZ, in Lahore an overwhelming 95.1% ofPage 3 of 6
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psychiatrist, while in Karachi only 41.2% of participants
had been initiated on BDZ by a psychiatrist. This differ-
ence was statistically significant (p < 0.001).
Discussion
In this survey on point prevalence of BDZ use in people
visiting psychiatry outpatient clinics for the first time in
two cities of Pakistan, about half (45%) of respondents
reported that they had been taking BDZ at the time of the
interview. Among the users 72% had been taking the BDZ
for 4 or more weeks and 87% had been taking it on a daily
basis.
Table 1: Association between sociodemographic and clinical 
variables and the likelihood of taking benzodiazepines
Variable Number (%) Taking BDZ P-value
Gender (n = 417) 0.058
Male 242 (57.9) 99 (40.9)
Female 176 (42.1) 89 (50.6)
Marital status(n = 419) 0.424
Married 249 (59.4) 116 (46.6)
Unmarried 170 (40.6) 72 (42.4)
Education (n = 419) 0.2
None 113 (27) 53 (46.9)
Primary 65 (15.5) 34 (52.3)
Secondary 81 (19.3) 37 (45.7)
Intermediate 47 (11.2) 16 (34)
Graduate 82 (19.6) 39 (47.6)
Postgraduate 31 (7.4) 9 (29)
Occupation (n = 418) 0.03*
Student 46 (11) 14 (30.4)
Professional 31 (7.4) 10 (32.3)
Housewife 118 (28.2) 66 (55.9)
Retired 9 (2.2) 5 (55.6)
Skilled labour 65 (15.6) 26 (40)
Businessman 30 (7.2) 9 (30)
Landlord 10 (2.4) 5 (50)
Unemployed 108 (25.8) 53 (49.1)
Unskilled labour 1 (0.2) 0 (0)
City (n = 419) 0.004*
Karachi 225 (53.7) 86 (38.2)
Lahore 194 (46.3) 102 (52.6)
Ever seen psychiatrist (n = 419) 0.009*
Yes 284 (67.8) 140 (49.3)
No 135 (32.2) 48 (35.6)
ICD-10 Diagnosis (n = 390) 0.053
F00-09 7 (1.8) 5 (71.4)
F10-19 19 (4.9) 14 (73.7)
F20-29 92 (23.6) 36 (39.1)
F30-39 193 (49.5) 90 (46.6)
F40-48 44 (11.3) 17 (38.6)
F50-59 2 (0.5) 0 (0)
F60-69 2 (0.5) 0 (0)
F70-79 2 (0.5) 0 (0)
F80-89 1 (0.3) 1 (100)
F90-98 1 (0.3) 0 (0)
No psych illness 27 (6.9) 10 (37)
* Statistically significant at the level of P < 0.05
• n is different for different variables as not all the participants had 
answered all the questions
Table 1: Association between sociodemographic and clinical 
variables and the likelihood of taking benzodiazepines (Continued)Page 4 of 6
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ies is made slightly difficult by different study criteria used
by different studies, particularly the definition of BDZ use,
population studied, and duration over which BDZ use
was measured[7] There were two previous studies from
Pakistan which had assessed BDZ prevalence. In the study
by Raoof et al in which the sample was outpatients and
visitors in general (non-psychiatric) outpatient clinics at a
tertiary care hospital, and which collected data on lifetime
prevalence, the prevalence was 30.4%[16] In the only
other study from Pakistan on this topic which looked at
the proportion of both non-psychiatric and psychiatric
inpatients who had been prescribed BDZ during their hos-
pital stay the point prevalence of BDZ prescription was
21.2%[11]
Studies from other parts of the world show that preva-
lence rates vary hugely ranging from 7.5% currently taking
a BDZ in French general population[15], 9.6% past
month use in Lebanese general population[19], 19.1%
taking BDZ regularly (one or more doses per week) at the
time of admission to a Sydney teaching hospital[10], 33%
taking BDZ at the time of admission to an Internal Medicine
unit in France[12], 41.4% prescribed BDZ to medical/sur-
gical inpatients in USA[9], and 86% lifetime prevalence of
BDZ use in patients admitted to a Swiss psychiatric hospi-
tal[8]. The 45% point prevalence of BDZ use in psychiatric
outpatients found in our study seems to be higher than
the prevalence found in previous studies from Pakistan,
and closer to the prevalence in inpatient units in interna-
tional studies.
Putting the three facts together that the drug had been ini-
tiated by a psychiatrist in 70% of the cases and doctors in
general in 89% of the cases, that 72% of users were taking
it for 4 or more weeks, and that 87% were taking it on a
daily basis, highlights the iatrogenic origin of this major
public health concern. Either the doctors are not educat-
ing patients about the maximum duration of how long
BDZ can be safely taken for, or the somehow the patients
are not receiving this message. Some research suggests that
the former hypothesis may be more accurate. A survey of
general practitioners in Thailand showed that about 23%
of general practitioners agreed that BDZ can be prescribed
regularly for more than 1 month and about 6% thought
that they could be prescribed for more than 4 months to
6 months[20] On the other hand, there is some research
evidence which suggests that patients tend to use less BDZ
medications than prescribed by their doctors which
refutes the second hypothesis[21]
The three variables which were significantly associated on
logistic regression with the likelihood of taking BDZ were
female gender, age and the city of residence. The finding
of an increased prevalence of BDZ use in females is very
consistent across studies and countries[7,15,19,22] One
possible explanation may be the higher prevalence of
mood and anxiety disorders in females as these two
groups of disorders accounted for over two thirds of all
patients in our study. Age has also been associated with
increasing risk of BDZ use in other studies[15,19]. How-
ever, the group taking BDZ in our study was only slightly
older that the group not taking BDZ (mean 35.8 vs 32.5
years) and the Odds Ratio 0.98 (95% C.I. 0.97–0.99) was
very close to 1, it is difficult to interpret this finding.
There were several statistically significant differences
between respondents in Karachi and Lahore in terms of
prevalence of BDZ use, difference between proportion of
females taking BDZ, and whether a psychiatrist had or had
not initiated the BDZ. In the absence of any previous
research in this area this needs to be studied more before
it can be interpreted meaningfully.
Though we inquired about the initiation of BDZ, we did
not assess as why the drug consumption continued, and
this can be regarded as a limitation of the study. We feel
that there may have been a communication gap either
from the side of the psychiatrist (might or might not have
advised BDZ continuation), or from the side of the patient
as he/she may not have complied with the psychiatrist's
advice.
Conclusion
In this study about half of the population studied had
been taking BDZ at the time of the interview, 72% of the
users had been taking the drug for than 4 or more weeks,
87% of users were taking it daily and in 90% of the cases
the BDZ had been initiated by a doctor. These finding
highlight the scale of this public health problem. In spite
of availability of modern dugs and psycho-therapeutic
measures, it shall not be easy to contain the subsequent
Table 2: Factors predicting the likelihood of taking a BDZ.
Variable Odds ratios* (95% C.I.) P-value
Age 0.98 (0.97–0.99) 0.01*
Gender 0.61 (0.40–0.95) 0.03*
Occupation 0.99 (0.90–1.09) 0.85
City 0.51 (0.31–0.81) 0.005*
Ever seen psychiatrist 1.56 (0.97–2.49) 0.06
ICD-10 Diagnosis 1.01 (0.98–1.03) 0.65
Simple Multiple Logistic Regression Analysis
* Statistically significant at p < 0.05Page 5 of 6
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problems and complications, as these measures would
inculcate some direct and indirect costs. Education, at reg-
ular intervals, may assist in controlling this issue remark-
ably.
The data suggests that the primary prevention of BDZ mis-
use must start with education of doctors in general and
psychiatrists in particular that they should educate every
patient they prescribe BDZ to about the potential of addic-
tion with these drugs.
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